The discovery of a higher mutation rate of two genes in tissue samples from African Americans with lung adenocarcinoma suggests that these patients may be particularly likely to benefit from drugs that target the PTPRT and JAK2 genes. The results were published December 16, 2019, in Nature Communications. Bríd Ryan, Ph.D., M.P.H., Investigator in CCR’s Laboratory of Human Carcinogenesis...
↧